Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07822100) titled 'To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hong Zhang
Condition:
IgA Nephropathy (IgAN)
Henoch Schonlein Purpura Nephritis
Intervention:
Diagnostic Test: Gd-IgA1 monitoring
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: August 24, 2026
Target Sample Size: 374
Countries of Recruitment:
China...